# Ian D. Davis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ian-d-davis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,276 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 74 |
| i10-index | 253 |
| Last Known Institution | Box Hill Hospital |
| OpenAlex ID | https://openalex.org/A5064732405 |
| ORCID iD | https://orcid.org/0000-0002-9066-8244 |
| Works | 697 |

## Researcher papers

- [Enzalutamide in Metastatic Prostate Cancer before Chemotherapy](https://scholariq.org/papers/enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy/)
- [Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer](https://scholariq.org/papers/enzalutamide-with-standard-first-line-therapy-in-metastatic-prostate-cancer/)
- [\[177Lu\]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial](https://scholariq.org/papers/177lu-lu-psma-617-versus-cabazitaxel-in-patients-with-metastatic-castration/)
- [Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-the-report-of-the-advanced/)
- [Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans](https://scholariq.org/papers/recombinant-ny-eso-1-protein-with-iscomatrix-adjuvant-induces-broad-integrated/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial](https://scholariq.org/papers/adjuvant-radiotherapy-versus-early-salvage-radiotherapy-following-radical/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [PSMA and FDG-PET as predictive and prognostic biomarkers in patients given \[177Lu\]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial](https://scholariq.org/papers/psma-and-fdg-pet-as-predictive-and-prognostic-biomarkers-in-patients-given-177lu/)
- [Overall survival with \[177Lu\]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial](https://scholariq.org/papers/overall-survival-with-177lu-lu-psma-617-versus-cabazitaxel-in-metastatic/)
- [\[177Lu\]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial](https://scholariq.org/papers/177lu-lu-psma-617-plus-enzalutamide-in-patients-with-metastatic-castration/)
- [Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-metastatic-and-or/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Box Hill Hospital](https://scholariq.org/institutions/box-hill-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.